Aims & Scope:

G protein-coupled receptors (GPCRs) belong to the largest receptor family, containing 800-1000 members. Each of these receptors has a seven-transmembrane domain, many of which have natural peptide or small molecule ligands. GPCRs are the most investigated and desirable drug targets in modern drug development, with almost half of the marketed drugs targeting GPCRs. The aim for this special issue is to review the current progression in such GPCR-associated fields as GPCR signaling, peptide ligands, small molecule ligands, receptor-targeted drugs, drug delivery systems and perspectives in developing GPCR-targeted drugs against cancers and other human diseases.

Keywords: G protein-coupled receptor (GPCR), Receptor-targeted drug, Drug delivery, Diseases, Cancer, Peptide-drug conjugate, Antibody-drug conjugate

Subtopics:

GPCR and drug development
Peptide-drug conjugates
Antibody-drug conjugates
Receptor-targeted drug in cancer therapeutics
Receptor-targeted drug in human diseases
Peptide-based drug development
Somatostatin and the analogs

Schedule:

Manuscript submission deadline: September 2014
Peer Review Due: October 2014
Revision Due: November 2014
Notification of acceptance by the Guest Editor: December 2014
Final manuscripts due: December 2014